PharmGen Science

PharmGen Science Stock-Based Compensation

The Stock-Based Compensation (SBC) of PharmGen Science (004720.KS) as of Oct 28, 2026 is 4.36 B KRW. In the previous year, Stock-Based Compensation (SBC) was 1.67 B KRW — a change of 160.83% (higher).

Stock-Based Compensation

4.36 BKRW

YoY

160.83%

Last updated:

Stock-Based Compensation (SBC) of PharmGen Science is 2021 4.36 B KRW. Stock-Based Compensation (SBC) of PharmGen Science was 2020 1.67 B KRW. It decreases by 160.83% higher compared to the previous year.

The PharmGen Science Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2016
452.63 M KRW
Jan 1, 2017
599.67 M KRW
Jan 1, 2018
366.64 M KRW
Jan 1, 2020
1.67 B KRW
Jan 1, 2021
4.36 B KRW
The PharmGen Science Stock-Based Compensation history
YEARStock-Based CompensationYoY
4.36 BKRW+160.83%
1.67 BKRW+355.85%
366.64 MKRW-38.86%
599.67 MKRW+32.49%
452.63 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmGen Science Stock analysis

What does PharmGen Science do? PharmGen Science, Inc. develops and produces medicaments including antiepileptic agents, anti-inflammatory agents, antiphlogistic agents, central nervous system agents, urinary agents, antihistamine agents, antivirus agents, agents for bones, agents for livers, calcium agents, antibiotics, diabetes agents, and respiratory agents. The company also manufactures over-the-counter (OTC) drugs, obesity drugs, and health food. Additionally, PharmGen Science engages in the manufacturing, wholesale, and retail distribution of functional cosmetics. Its products are distributed within the domestic market and to overseas markets. The company's primary revenue streams come from the sale of its pharmaceutical products and functional cosmetics. Pharmaceutical products include both prescription medications like antiepileptic agents and OTC drugs such as obesity drugs. Functional cosmetics are sold through wholesale and retail channels. The domestic market serves as the main sales channel while international distribution supports global reach. PharmGen Science targets healthcare providers, pharmacies, and consumers for its pharmaceutical products. The domestic market is a key segment for prescription drugs and OTC products. Overseas markets represent an additional segment for both pharmaceuticals and cosmetics. Functional cosmetics are distributed through retail and wholesale channels to end consumers and beauty retailers. PharmGen Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmGen Science stock

Stock-Based Compensation (SBC) of PharmGen Science is 4.36 B KRW in 2021.

Stock-Based Compensation (SBC) of PharmGen Science changed from 1.67 B KRW to 4.36 B KRW, representing a 160.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) PharmGen Science since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s PharmGen Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PharmGen Science

All Key Metrics — PharmGen Science